Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

NCT ID: NCT05540028

Last Updated: 2023-08-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 65 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-28
• Study Completion Date: 2023-07-31

Brief Summary

A first-in-human, Phase 1 trial to evaluate safety, tolerability, and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25)

Detailed Description

A first-in-human, multicenter, randomized, active-controlled, observer-blind Phase 1 study of IVT PCV-25 designed to evaluate the safety, tolerability, and immunogenicity of the vaccine. Adult subjects will be randomized 1:1 to receive either IVT PCV-25 or Prevnar 20™.

Conditions

Pneumococcal Vaccines

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Adult Cohort Group 1

Participants will receive a single 0.5mL dose of IVT PCV-25 administered by intramuscular injection on Day 1

Group Type: EXPERIMENTAL

IVT PCV-25

Intervention Type: BIOLOGICAL

25 valent pneumococcal conjugate vaccine

Adult Cohort Group 2

Participants will receive a single 0.5mL dose of PCV 20 administered by intramuscular injection on Day 1

Group Type: ACTIVE_COMPARATOR

PCV 20

Intervention Type: BIOLOGICAL

20 valent pneumococcal conjugate vaccine

Interventions

PCV 20

20 valent pneumococcal conjugate vaccine

Intervention Type: BIOLOGICAL

IVT PCV-25

25 valent pneumococcal conjugate vaccine

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Healthy adults who are 18 through 40 years old on the day of randomization (Day 1).
• Subject, or subject's LAR, must provide voluntary written informed consent for the subject to participate in the study.
• Subject or subject's LAR must be able to comprehend and comply with study requirements and procedures and must be willing and able to return for all scheduled follow-up visits.
• There will be an allowance though not a requirement for COVID-19 vaccination in all participants in compliance with Canadian national recommendations.
• Adult female subjects who are not surgically sterile must have a negative serum pregnancy test at screening and negative urine pregnancy test prior to vaccination.

Exclusion Criteria

• Use of any investigational medicinal product within 90 days prior to randomization or planned use of such a product during the period of study participation.
• Adults who have previously been vaccinated against S. pneumoniae.
• History of microbiologically confirmed invasive disease caused by S. pneumoniae.
• History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.
• Known or suspected allergy to PEG.
• History of angioedema.
• Any abnormal vital sign deemed clinically relevant by the PI.
• Acute illness (moderate or severe) and/or fever (body temperature of ≥ 38.0°C)
• Use of antibiotics (oral or parenteral) within 5 days of randomization.
• History of administration of any non-study vaccine (e.g. influenza; COVID-19 vaccine) within 14 days of first administration of study vaccine or planned vaccination prior to 14 days post-vaccination blood draw.
• Chronic administration (defined as more than 14 consecutive days) of immunosuppressant or other immune modifying drugs prior to the administration of the study vaccine (and within the 6 months prior to administration of the study vaccine in the case of adults), including the use of glucocorticoids. The use of topical and inhaled glucocorticoids will be permitted.
• Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine, or anticipation of such administration during the study period.
• History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding (e.g., thalassemia, coagulation factor deficiencies, severe anemia).
• Any medical or social condition that in the opinion of the PI , may interfere with the study objectives, pose a risk to the subject, or prevent the subject from completing the study follow-up.
• Subject is an employee of, or direct descendant (child or grandchild) of any person employed by the Sponsor, PATH, the CRO, the PI.
• A positive serologic test for human immunodeficiency virus (HIV)-1 or HIV-2 (HIV 1/2 Ab), hepatitis B (HBsAg) or hepatitis C (HCV Ab).
• History of malignancy, excluding non-melanoma skin and cervical carcinoma in situ.
• Recent history (within the past year) or signs of alcohol or substance abuse.
• History of major psychiatric disorder.
• Female adult subjects who are pregnant or breastfeeding

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Canadian Center for Vaccinology

OTHER

Sponsor Role: collaborator

Vaccine Evaluation Center, Canada

OTHER

Sponsor Role: collaborator

PATH

OTHER

Sponsor Role: collaborator

Inventprise Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Joanne Langley, MD, MSc, FRCPC

Role: PRINCIPAL_INVESTIGATOR

Canadian Center for Vaccinology

Locations

Canadian Center for Vaccinology, IWK Health Centre

Halifax, Nova Scotia, Canada

Countries

Canada

Other Identifiers

CVIA 096

Identifier Type: -

Identifier Source: org_study_id